Jacob Aelion

3.6k citations

46 papers · 1.8k indexed · h-index 20

Impact in

Rheumatology top 1%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Immunology top 2%
- Psoriasis: Treatment and Pathogenesis
- T-cell and B-cell Immunology

Papers in

Rheumatology 28
- Rheumatoid Arthritis Research and Therapies 18
- Spondyloarthritis Studies and Treatments 12
Hematology 16
- Autoimmune and Inflammatory Disorders Research 15

Co-authors: Hanno B. Richards Malak Kotb Mark C. Genovese Paul Bird Christopher J Edwards Eva Dokoupilová Sophie Hugot Herbert Kellner
Journals: Annals of the Rheumatic Diseases (17 papers)Lara D. Veeken (4 papers)Cellular Immunology (2 papers)Rheumatology and Therapy (2 papers)The Journal of Rheumatology (2 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Jacob Aelion

45 papers receiving 1.7k citations

Peers

Countries citing papers authored by Jacob Aelion

Since Specialization

Citations

This map shows the geographic impact of Jacob Aelion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob Aelion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob Aelion more than expected).

Fields of papers citing papers by Jacob Aelion

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob Aelion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob Aelion. The network helps show where Jacob Aelion may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jacob Aelion, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jacob Aelion Line = papers co-authored together Jacob Aelion links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial Rheumatology and Therapy ·Andrew J.K. Östör, Filip Van den Bosch, Kim Papp, 若原弘之, Ricardo Blanco, Jacob Aelion, 森尾登, Ng Charlene, Ralph Lippe, Febie Elfaladonna, Ahmed M. Soliman, Michael M. Chen, Eduardo Luiz Dias Cavalcanti, Alan Kivitz	2024	9
2	Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial SKIN The Journal of Cutaneous Medicine ·Andrew J.K. Östör, Filip Van den Bosch, Kim Papp, 若原弘之, Ricardo Blanco, Jacob Aelion, Carly Munro, Amelia Wahyu Noor Aida, Fang Liu, Ahmed M. Soliman, Wilda Devy Anjani, Lila Glotfelty, Alan Kivitz	2024	0
3	Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial Annals of the Rheumatic Diseases ·Laure Gossec, Laura C. Coates, Dafna D. Gladman, Jacob Aelion, Maria dos Remédios de Brito, Andreas Pinter, Joseph F. Merola, Arthur Kavanaugh, Palash Sen, Rebecca Wang, Michèle Brunori, 敏彦岡田, Huanda Guan, Philip J. Mease	2024	4
4	Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial Arthritis Research & Therapy ·Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Hendrik Stilke, 俊哉鯉田, Atul Singhal, Jerzy Świerkot, Nasser Khan, J. F. Wang, Yihan Li, Mayumi Arellano-Lino, Heidi S. Camp, Jacob Aelion	2024	5
5	Optimizing oral immune tolerance to Type II collagen in patients with rheumatoid arthritis: The importance of dose, interfering medication and genetics The American Journal of the Medical Sciences ·Arnold E. Postlethwaite, Yan Jiao, Chengyuan Yang, Wei Dong, Jacob Aelion, Benjamin Wang, Bennett E. Postlethwaite, Leonard H. Sigal, Andrew H. Kang, Linda K. Myers, Max Schulze, Jesse Ingels, Weikuan Gu	2024	1
6	Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial Arthritis & Rheumatology ·Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich, 陈冬贵, Su Chen, Yang� Yang, Dilek Arikan, Ronilda D’Cunha, Yinuo Pang, H. Küpper, Timothy R. D. J. Radstake, Howard Amital	2022	31
7	THU0195 INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM Annals of the Rheumatic Diseases ·Navneet Sarhadi, Iain B. McInnes, J. Cush, Jacob Aelion, William F. C. Rigby, Yong Song, Sebastian Meerwein, 付志风, Jose Luis Pech, Deppmeyer, Vladislav Khvostov	2020	7
8	Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study Rheumatology and Therapy ·Hasan Tahir, Atul Deodhar, Mark C. Genovese, Tsutomu Takeuchi, Jacob Aelion, Filip Van den Bosch, Sibylle Haemmerle, Hanno B. Richards	2017	27
9	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Annals of the Rheumatic Diseases ·Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, C. Birbara, Janusz Jaworski, Jacob Aelion, Randall M. Stevens, Adele R. Vessey, Xiaojiang Zhan, Paul Bird	2016	215
10	One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study The Journal of Rheumatology ·Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilová, Jacob Aelion, Sang‐Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Gregory Ligozio, Shephard Mpofu	2014	83
11	Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study Annals of the Rheumatic Diseases ·Mark C. Genovese, Patrick Durez, Hanno B. Richards, Jerzy Supronik, Eva Dokoupilová, Mazurov Vi, Jacob Aelion, Sang‐Heon Lee, Christine E. Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Shephard Mpofu	2012	227
12	Extraosseous Uptake of Tc-99m HDP in Muscular Dystrophy Clinical Nuclear Medicine ·Bárbara Rabelo, Jacob Aelion, Ribera Teresa, Dinda Rosalinda	2000	1
13	Evidence for Preferential T Cell Receptor Vβ Gene Usage and T Cell Clonal Expansion in the Synovium of BB Rats with Early-Onset Collagen-Induced Arthritis Cellular Immunology ·Shashank Singh, Jacob Aelion, Robert O. Endres, Andrew H. Kang, Michael A. Cremer	1998	3
14	Variable-Region Gene Family Usage for Type II Collagen Autoantibodies in Arthritis-Susceptible DBA/1 Mice Clinical Immunology and Immunopathology ·Shashank Singh, Tony N. Marion, Kuniaki Terato, Jacob Aelion, Michael A. Cremer, David M. Tillman, Marc S. Krug, Benita Jackson, Tai June Yoo	1996	3
15	Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. Journal of Clinical Investigation ·Donald Y.M. Leung, Jeffrey B. Travers, Ralph Giorno, David A. Norris, Akhmad Toha, Jacob Aelion, Leila Kazemi, 久雄平田, Anne E. Trumble, Malak Kotb	1995	225
16	Treatment of calcinosis with diltiazem Arthritis & Rheumatism ·Genaro M. A. Palmieri, Jeno Sebes, Jacob Aelion, T B Ekogo, Morris W. Ray, G. Christopher Wood, Kun Wang	1995	64
17	Role of the conserved histidine and aspartic acid residues in activity and stabilization of human gelatinase B: An example of matrix metalloproteinases Journal of Protein Chemistry ·Tayebeh Pourmotabbed, Jacob Aelion, D.J. Tyrrell, Karen A. Hasty, Chun Hui Bu, Carlo L. Mainardi	1995	10
18	Preservation of the Specificity of Superantigen to T Cell Receptor Vβ Elements in the Absence of MHC Class II Molecules Cellular Immunology ·Malak Kotb, O.A. Osonuga, Jacob Aelion, Terukazu Tanaka, Arthur M. Geller, Hiroaki Ohnishi	1993	8
19	T cell receptor V gene usage by human T cells stimulated with the superantigen streptococcal M protein. The Journal of Experimental Medicine ·Mark A. Tomai, Jacob Aelion, Michael E. Dockter, G Majumdar, Dominic G. Spinella, Malak Kotb	1991	73
20	Eosinophilic Pleural Effusion: A Review of 36 Cases Respiration ·Arjeh J. Wysenbeek, Meir Lahav, Jacob Aelion, Qi-Jing Xu	1985	36

About Jacob Aelion

Jacob Aelion is a scholar working on Rheumatology, Hematology, Immunology, Genetics and Immunology and Allergy, having authored 46 papers that have together received 1.8k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (18 papers), Autoimmune and Inflammatory Disorders Research (15 papers), Spondyloarthritis Studies and Treatments (12 papers), Psoriasis: Treatment and Pathogenesis (12 papers), Chronic Lymphocytic Leukemia Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Immunodeficiency and Autoimmune Disorders (5 papers) and Immunotherapy and Immune Responses (4 papers). The work is most often cited by research in Rheumatology (926 citations), Immunology (1.1k citations), Hematology (496 citations), Dermatology (238 citations) and Immunology and Allergy (42 citations). Jacob Aelion has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Hanno B. Richards, Malak Kotb, Mark C. Genovese, Paul Bird, Christopher J Edwards, Eva Dokoupilová, Sophie Hugot, Herbert Kellner, Christine E. Codding and Patrick Durez. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Cellular Immunology, Rheumatology and Therapy and The Journal of Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact